Explore research articles and continuing education for radiopharmaceutical therapies, including recorded content from SNMMI meetings, webinars, and more.

Continuing Education

SNMMI has compiled a comprehensive list of available educational activities related to radiopharmaceutical therapy. We encourage you to check frequently, as this content will continue to be updated monthly.

Clinical Practice | Dosimetry | General | Liver | NETs | Prostate | Thyroid

 

The SNMMI 2022 Therapeutics Conference

New Dates: March 10-12, 2022 | New Orleans, Louisiana

Attend the SNMMI Therapeutics Conference, in-person, March 10-12, 2022 at the Hyatt Regency New Orleans. This two-and-a-half-day event will explore the latest innovations and clinical applications in radiopharmaceutical therapy. 

2022 SNMMI Mid-Winter and ACNM Annual Meeting

January 27-29, 2022 | Orlando, Florida

The 2022 SNMMI Mid-Winter and ACNM Annual Meeting will feature several sessions on theranostics, including:

  • Theranostic Nuclear Medicine is Coming-of-Age!
  • Updates in Theranostics in Prostate Cancer 
  • Nuclear Medicine Theranostics in Neuroendocrine tumors: Taming the Zebras
  • Theranostics Around the World
  • Flipped Learning Session with a Focus on Theranostics  
Learn more about the educational program.

SNMMI 2021 Mid-Winter Meeting—Dedicated Therapy Track 

SNMMI—the leader in radiopharmaceutical therapy education—shared up-to-date overviews of key areas during a dedicated therapy track at the 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting. 

Therapy track sessions included:

  • The Nuts and Bolts of IV Radiopharmaceutical Therapy Administration
  • Prostate Cancer PSMA Therapy
  • Updates on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications
  • Updates and Clinical Applications of PRRT for NET
  • Radioiodine Therapy for Differentiated Thyroid Cancer
On-demand sessions are currently available for purchase in the SNMMI Learning Center.

SNMMI 2019 Therapeutics Conference

The two-and-a-half-day SNMMI Therapeutics Conference: Therapies, Theranostics, and Building Your Radionuclide Clinical Practice, explored the latest innovations in therapy, including acquiring the knowledge and resources to effectively deliver theranostics agents and the fundamental steps necessary to establish a nuclear medicine therapy program at your institution.

Third Targeted Radionuclide Therapy Conference   

SNMMI and the National Cancer Institute (NCI) held the Third Targeted Radionuclide Therapy Conference in December 2019. Invited attendees representing the major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives, held discussions on maximizing dose to tumor while sparing normal tissue, the current state of the science, state-of-the-art clinical trial design, and strategies for achieving response.

2018 Theranostics Consensus Conference

The SNMMI/National Cancer Institute (NCI) 2018 Theranostics Consensus Conference focused on key elements within this evolving field of nuclear medicine, including the current state of theranostic technology, challenges in trial design, and the training and requirements needed for administration and dose planning. With all stakeholders represented, participants had productive discussions on developing guidelines for efficient clinical trials, the drug approval process, and the best ways to collect necessary data for both timely and reasonable reimbursements and successful regulatory filings.

  • View Slides from the 2018 Theranostics Consensus Conference: Day 1 | Day 2
__

JNM

View the most recent content from The Journal of Nuclear Medicine (JNM) related to radionuclide therapy. 

Access JNM Therapy content.

JNMT

View the most recent content from the Journal of Nuclear Medicine Technology (JNMT) related to radionuclide therapy. 

Access JNMT Therapy content.

Featured Video


In the highly attended Theranostics: Regulatory Considerations for Product Development session at the SNMMI 2019 Annual Meeting in Anaheim, California, speakers examined clinical, nonclinical and CMC information needed for theranostics product development, including a discussion on regulatory perspectives of products combining an imaging modality with therapeutic radiopharmaceuticals.